Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Im not saying there wont be another r/s but Im pretty sure if there is another one it wont be 1 for 50. I'm pretty sure when a company gets bought they only get paid out on the issued shares. I know the total diluted share count for Intellect is around 650 million, however I still dont believe all those notes will be converted to bring the share count that high. I also dont believe that Intellect is going to be bought out, Intellect plans to become its own self sustaining company. They have a lot in their pipeline that could lead to a few potential blockbuster drugs.
I dont believe the payment will affect the share price much...maybe a slight pop up. I would just like to hear that they received it, because according to their last co statement they only had a little over $200,000 on hand. It is my thinking that they must be pretty confident that they will receive the payment and maybe other milestone payments because of all the recent spending Intellect has done in acquiring new mabs and beginning preclinicals with RV03.
Hoping to hear about the milestone payment this week. I am still hoping we hear about the US n-terminus patent before the non-carrier trial for Bapi is complete in August.
I believe Intellect will partner up with a Big Pharma company before clinicals begin for IN-N01-OX2. In their latest Corp Presentation they touch on that possibility. With a current 4 billion dollar market for wet AMD I think Intellect will receive a deal from Big Pharma that will make the OX1 deal with Viopharma look small.
Thanks, do you have any insight on the preferred shares? ...or am I just totally off the mark with my thinking on them?
I wonder how the Neurotech Investing and Partnering Conference went on the 21st. I hope if they do get new financing it wont involve any more preferred shares. I was wondering do those preferred shares have to be eventually converted by the holders or the company? ..or can there be a new agreement made and have those preferred shares done away with? Just asking because it seems if Intellect begins to receive revenue from bapi if and when it is approved they could repay the lenders over time without having all those shares put into the Outstanding Count. Seeing how those preferred shareholders more than likely have millions of common shares as well? Any feedback would be appreciated.
New presentation is on Intellects website. http://content.stockpr.com/intellectns/media/d58aaf7b67c66fcf7837102deeddaa6a.pdf. I am very excited about IN-N01-OX2, in their presentation the company says that it plans to partner with Big Pharma in phase 1 or earlier! I believe the deal for IN-N01-OX2 will make the Viopharma deal for OX1 look small. This is a very near future development as per the presentation Intellect plans to take IN-N01-OX2 into phase 1 by 2014!
I misunderstood your post. I thought you were saying he was behind bars, I agree with you that he might not do any time at all.
Blech is not behind bars yet. He has pleaded guilty and is out on bail. He hasnt been sentenced yet, I believe his lawyer is trying to get the sentencing delayed as long as he can. I agree with you that there are a lot of positives with Intellect. I would like to hear about what is going on with their n-terminus patent with the USPTO though. All the news out lately is very good for the future of the Company but the us patent would be HUGE for the company right now.
Has anyone seen this? http://www.streetinsider.com/Analyst+Comments/Elan+Corp+(ELN)+Up+on+Positive+FDA+Alzheimers+Disease+Comments/7441223.html I believe this helps Bapis chances of getting approved tremendously!!
I think the fact that Intellect says that a well known pharma company is already showing interest in obtaining IN-N01-OX2 is HUGE!!
The non-carrier group is set to complete in August. So Im thinking the earliest mid September.
The non-carrier group is set to complete in August. So Im thinking the earliest mid September.
Well sir, I guess we just have two very different opinions. Best of luck to you, and again thank you for replying.
The case for Bapi will be made when phase 3 data comes out. I dont think ripping articles form other sites and posting them will make my case. I give Bapi a good chance at approval because it showed that it had an affect on the levels of p-tau in the brain, which is believed to cause tangles. It was also mentioned in the April 4th article released this year that cognitive function may have improved in some non carriers during the phase 2 trials. Im sure this study was expanded upon and explored in greater detail in the phase 3 trials. You say that Aricept does little for Alzheimer's, yet it makes billions in sales globally each year. My wifes grandmother was on Aircept, it it definitely helped her, I feel Bapi will be an improvement on Aircept. Thats pretty much my case thus far
Thanks for the response. I strongly disagree with you about Bapi not having a chance, and Intellects royalty's being nominal from it if approved. Like I said though I dont mind hearing anything negative, it gives me more to research.
Thanks for the info...good to know. If I may pick your brain just once more...I have read through some past posts from this board and you seem to be pretty negative on the stock to say the least. lol. I dont mind hearing any negatives, Im always open to any information. So anyway heres my question, if Bapineuzumab shows positive phase 3 data (which I believe it will for the non-carrier group) and then eventually received approval from the FDA do you think that would have a positive impact on this stock?
What makes you think the lifted CT order relates to patents?
bee63 IMO I think the stock is trading down because of lack of news with Intellects n-terminus amyloid US patent. I believe when and if they get the approval for that patent the stock will go higher as this would greatly increase Intellects revenue stream for Bapi if it gets FDA approval. The dip in the stock this week I feel is some people just selling because of the stagnation of the stock price these past few months. As far as I have researched nothing has changed to make the sock price go down, but as we all know in penny land large fluctuations up and down in stock price happen without reason.
If there is no patent news before phase 3 data for Bapi is released, I can see the price trading in the .03 to .05 range. However when The Bapi info is released and if it is positive (which I believe the non carrier group info will be) then I can see the stock going a lot higher being Intellect still has patents in China and Japan for Bapi which will still bring in millions of dollars of revenue! The price could also move higher on any milestone payments that they might receive between now and Bapis phase 3 data.
Im not to concerned with the day to day price of this stock, Im here waiting on patent news and Bapi data and approval. If you stop and think about it though Bapi approval and revenues from it may just be the tip of the Iceberg for this company. The deal they made with Viopharma is the direction I believe they are headed. Intellect will start to bring their own science into development and when they show the first or second phases have positive results Big pharma companies will partner up with them to finish development of their drugs. Giving them larger milestone payments and larger royaltys on the drugs developed. Can you imagine what a big pharma company would give Intellect if their RV03 vaccine showed that it had a good chance of halting or even preventing Alzhiemer's?!
Wow, I went on a pretty big ramble there lol. GL
Go to www.scarletroadstudy.com and click on What is Prodromal Alzheimer's. This is what the new phase 3 study would be for, to see if Bapi would be appropriate to give to people with this very beginning stage of the Disease. This should not delay the current phase 3 data to be presented this year, nor should it interfere FDA approval or disapproval for Bapi to be used for mild to moderate Alzheimer's.
I beleive the follow up study is to see if Bapi could be used to treat people with earlier symptoms of Alzheimers.
Sorry Typo...Alex Gorsky
New CEO of JNJ Alex Grosky made a quick but pretty powerful comment about Bapi today on CNBC'S Closing Bell. He said that he was particularly excited about the long term prospects of Bapineuzumab. Im pretty sure this man has access to the phase 3 results of Bapi thus far and has been briefed on those results. It is good to hear someone from JNJ make a positive comment about Bapi no matter how brief! We are getting closer everyday, hope we hear more about the US patents for Intellect soon!
Huh? lol. That sure is a lot of info there. Im not sure if you are asking me if Intellect is using that white noise angle to get the patent or what. Interesting read though. Thank you
The Bapineuzumab phase 3 carrier trials are complete as of April 20th acoording to clinicaltrials.gov! We are so close to hearing about the data from this trial! Come on Intellect get that US patent!!!
Great DD buckiii2! It seems for every negative article I read about Bapi there is a positive one about it. I guess there are negative articles because of the failures of other similar types of alzheimers drugs and people are skeptical. Then I see the positive articles about Bapi that show how it works differently then the other drugs that have failed. I think a lot of skepticism for Bapi is in the share price of Intellect. Still trying to find out the status of the US patent for the n-terminus amyloid, no luck so far.
Well JNJ remained pretty tight lipped on Bapi during their conference call. They didnt even answer the one question asked about it during the QA. They just said they would give the results later this year, not sure if them remaining quiet about Bapi is good or bad. I like that Intellect is moving ahead with RV03, not the news I was hoping to hear at this point but still good news.
I hope JNJ gives an update on Bapi during their conference call 2morrow. Im dying to hear any type of positive news! lol
A USTPO approval for their n-terminus patent and Bapinezumab getting an FDA approval alone could make this a 50 bagger. Intellect would have a steady stream of revenue coming in, if the drug made 2 billion in sales (which I believe would be on the low end) Intellect could see 100 million dollars from it!! Besides any milestone payments due to them from other pharma companys for the development from other drugs. So much hinges on this Bapi approval and USTPO decision, this would be huge for almost any company let alone a .05 Pink Sheet company!!
Great DD Buckiii2!! I think its only a matter of time before a big pharma company tries to partner up with Intellect to try and develop RVO1, RV02 and RV03! I cant even begin to start to speculate what a vaccine like RV03 would bring in as revenues!!
Called the Transfer Agent again this morning and the oustanding share count is still 86.8 million. I like the fact that there are not hundreds of millions or billions of shares in the outstanding count. Also I found that the company will speaking at a conference in San francisco Aug 6-8.
Just reviewed the October 14 2011 PR from Intellect and it states that they expect the European appeal decision to take at least 2 years. So this would mean Intellect would get a decision at its earliest in July 2013. I am still trying to find out if they have any chance of getting the approval on the US patent for the n-terminus patent before the Bapi phase 3 results come out. All I keep finding is the US approval for the c-terminus patent for the drug Ponzeumab, with no mention of when they expect to hear about the n-terminus patent. I could sure use a crystal ball right about now...lol
Thanks for the welcome. I have been tracking this company for the past 4 months and decided to pull the trigger and buy some last month. It was good to hear from the T/A that there havent been hundreds of millions of shares put into the float since their Feb 2 release of there financials. Only 8 million have been added since. The Bapi patent approval from the ustpo would really be a game changer for this stock IMO! This company would be seeing some serious revenues by the end of 2013 if the drug is fast tracked. This is a high risk- high reward play...I usually stay away from any company that has had a reverse split...let alone a 1 for 50 rs, but I feel the potential is here for Intellect to become that once in a lifetime stock. GLTA
Thanks buckiii2, I punched in pf-04360365 and saw that there is one open phase 1 trial still ongoing but not recruiting. I am hoping like hell that Intellect gets the USTPO approval for their n-terminus patent before the Bapi results come out. As long as the company doesnt dump a ton of shares into the outstanding count I believe this stock will skyrocket on that news alone. I dont know if that is a possibility, but I know they started their appeal for that patent a while ago. The European appeal just started last year so Im guessing that is going to take some time.
I have a question for the board. I know that Intellect has a stake in Bapineuzumab in certain countries but is being contested in Europe and the United States, and I know that Intellect has a stake in Ponezumab...Pfizers drug that they discontinued in phase 2. My question is does anyone know if Intellect has a stake in Solanezumab.. Lillys drug that is wrapping up its phase 3 trials? Thanks in advance
I just recently called the Transfer agent of this company and was told that there are 86.8 million shares oustanding.